🔴 Lipocine is trading 6.4% down in after-hours trading with no late-breaking catalyst identified

Lipocine is trading 6.4% down at $2.06 after-hours; available reporting does not identify a late-breaking catalyst.

• Lipocine closed the October 7, 2026 regular session at $2.20.
• On October 7, Lipocine announced Health Canada approval of TLANDO® through partner Verity Pharmaceuticals, which plans a Canadian launch by year-end. The release did not link the news to the after-hours decline.
• Major U.S. indices were also lower, but the supplied moves do not establish a cause.